AFT Pharmaceuticals: AFT Pharmaceuticals Collaborates with Hyloris Pharmaceuticals to Develop A Novel Innovative Injectable Iron Deficiency Therapy

AFT Pharmaceuticals announced confirmation of a new agreement to develop a novel innovative injectable iron deficiency therapy. The agreement caps off the strong progress the diversified pharmaceutical company has made in the 2025 financial year. The late-stage research and development program for the New Chemical Entity (NCE) is a collaboration with Belgium's Hyloris Pharmaceuticals. The product holds out the potential for some significant and unique features to alleviate iron deficiency, a common condition that affects 15% of the world population. It offers AFT and its partners entry into a market which is forecast to more than double from around USD 3. 2 billion in 2023 to USD 7. 4 billion in 2033. The NCE Injectable Iron is a well-advanced R&D project having completed Phase 2b trials. Once commercialised it will extend AFT's strong position in iron medicines in the over-the-counter channel, into the prescription channel. AFT's current OTC portfolio includes Ferro-liquid, FerroTab, Ferro-F-Tab, Ferro-sachets, Ferro Liposachets and FerroMalt which cumulatively represents a significant position in the Australasian iron medicines market. Under the terms of the original conditional agreement -- first flagged in October 2024 -- upon meeting pre-specified conditions, AFT and Hyloris secure an exclusive global IP license for the NCE Injectable Iron and together with the original development company they will co-develop the medicine for registration and global commercialisation. Hyloris will oversee product formulation, manufacturing, and the coordination of commercialisation in Europe. AFT will manage the clinical trials, execution and the commercialisation outside Europe which will include the world's second and third largest pharmaceutical markets - China and Japan. The duo is jointly responsible for commercialisation in the US, the world's largest pharmaceutical market. Phase 3 clinical trial(s) involving approximately 1000 patients will be conducted across the globe in USA, Europe, India and China for investigation of the products efficacy and safety. Development costs, as well as all net margin from sales and licensing, will be distributed equally between AFT and Hyloris, after a tiered profit participation for the original development company. The agreement extends AFT's partnership with Hyloris. The companies successfully collaborated to commercialise Maxigesic IV, the intravenous version of AFT's patented pain relief medicine now sold in 50 countries and out-licensed to partners for distribution in a further 50+ countries. AFT is also collaborating with the Belgian company to develop and commercialise a new treatment for Burning Mouth Syndrome and another for Vulvar Lichen Sclerosis, both conditions without approved pharmaceutical treatments. AFT Pharmaceuticals announced confirmation of a new agreement to develop a novel innovative injectable iron deficiency therapy. The agreement caps off the strong progress the diversified pharmaceutical company has made in the 2025 financial year. The late-stage research and development program for the New Chemical Entity (NCE) is a collaboration with Belgium's Hyloris Pharmaceuticals. The product holds out the potential for some significant and unique features to alleviate iron deficiency, a common condition that affects 15% of the world population. It offers AFT and its partners entry into a market which is forecast to more than double from around USD 3. 2 billion in 2023 to USD 7. 4 billion in 2033. The NCE Injectable Iron is a well-advanced R&D project having completed Phase 2b trials. Once commercialised it will extend AFT's strong position in iron medicines in the over-the-counter channel, into the prescription channel. AFT's current OTC portfolio includes Ferro-liquid, FerroTab, Ferro-F-Tab, Ferro-sachets, Ferro Liposachets and FerroMalt which cumulatively represents a significant position in the Australasian iron medicines market. Under the terms of the original conditional agreement -- first flagged in October 2024 -- upon meeting pre-specified conditions, AFT and Hyloris secure an exclusive global IP license for the NCE Injectable Iron and together with the original development company they will co-develop the medicine for registration and global commercialisation. Hyloris will oversee product formulation, manufacturing, and the coordination of commercialisation in Europe. AFT will manage the clinical trials, execution and the commercialisation outside Europe which will include the world's second and third largest pharmaceutical markets - China and Japan. The duo is jointly responsible for commercialisation in the US, the world's largest pharmaceutical market. Phase 3 clinical trial(s) involving approximately 1000 patients will be conducted across the globe in USA, Europe, India and China for investigation of the products efficacy and safety. Development costs, as well as all net margin from sales and licensing, will be distributed equally between AFT and Hyloris, after a tiered profit participation for the original development company. The agreement extends AFT's partnership with Hyloris. The companies successfully collaborated to commercialise Maxigesic IV, the intravenous version of AFT's patented pain relief medicine now sold in 50 countries and out-licensed to partners for distribution in a further 50+ countries. AFT is also collaborating with the Belgian company to develop and commercialise a new treatment for Burning Mouth Syndrome and another for Vulvar Lichen Sclerosis, both conditions without approved pharmaceutical treatments.